About
IHP Therapeutics is developing IHP-102 for the treatment of acute vaso-occlusive crisis in sickle cell disease. Empowering individuals with sickle cell, IHP-102 aims to be the first self-administered rescue therapeutic, moving care to the home setting and avoiding costly and ill-equipped healthcare systems.
Our Team
Board of Directors
Rinko Ghosh, MS, MBA
​
Vlad Hogenhuis, MD, MBA
John Paderi, PhD
​
​
Our Team
Rinko Ghosh, MS, MBA
President and CEO
John Paderi, PhD
CSO
Gabriel Njikang, PhD
CMC
Kate Stuart, PhD
VP of Program Management
​
Peggy McLaughlin
Clin. Ops. Advisor
Nathan Bachtell, MD
Clinical Advisor
Robert Van Gorp
Strategic Sourcing
Board of Directors
Rinko Ghosh, MS, MBA
​
Vlad Hogenhuis, MD, MBA
John Paderi, PhD
​
​
Clinical and Scientific Advisors
Science
IHP-102 is a novel dual P-selectin and complement inhibitor, which are two key mechanisms of vaso-occlusion in sickle cell disease. During acute vaso-occlusive pain crises, blockade of these mechanisms shows strong promise for disease-modifying effect and could reduce both pain symptoms and the tissue and organ damage cause by this devastating condition.
Pipeline
Contact:
​
​
IHP Therapeutics has recently been made aware of a growing number of email scams targeting job candidates in the biotech industry. IHP exclusively uses @ihptherapeutics.com email addresses for any and all communication. We do not ask candidates to purchase anything, nor do we ask for any sensitive information via email. If a person claiming to represent IHP with an alternative email domain reaches out to you regarding a job posting, please report it to our team by emailing info@ihptherapeutics.com. Thank you.